Genentech Hits Consensus, But Avastin Sales Trouble Analysts Jan. 12, 2005 While Genentech Inc. logged a 43 percent jump in total product sales for 2004, analysts scrutinized the company's sales of Avastin, calling them modest and lethargic at best. (BioWorld Today)Read More
RSS